|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UNC50 |
Gene summary for UNC50 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UNC50 | Gene ID | 25972 |
| Gene name | unc-50 inner nuclear membrane RNA binding protein | |
| Gene Alias | GMH1 | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | J3KQ47 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25972 | UNC50 | LZE4T | Human | Esophagus | ESCC | 5.25e-08 | 4.29e-01 | 0.0811 |
| 25972 | UNC50 | LZE5T | Human | Esophagus | ESCC | 1.59e-05 | 4.13e-01 | 0.0514 |
| 25972 | UNC50 | LZE7T | Human | Esophagus | ESCC | 1.84e-04 | 4.49e-01 | 0.0667 |
| 25972 | UNC50 | LZE8T | Human | Esophagus | ESCC | 1.31e-08 | 3.88e-01 | 0.067 |
| 25972 | UNC50 | LZE22T | Human | Esophagus | ESCC | 7.82e-05 | 6.96e-01 | 0.068 |
| 25972 | UNC50 | LZE24T | Human | Esophagus | ESCC | 2.86e-23 | 6.96e-01 | 0.0596 |
| 25972 | UNC50 | LZE21T | Human | Esophagus | ESCC | 2.01e-04 | 3.68e-01 | 0.0655 |
| 25972 | UNC50 | P1T-E | Human | Esophagus | ESCC | 2.92e-05 | 5.41e-01 | 0.0875 |
| 25972 | UNC50 | P2T-E | Human | Esophagus | ESCC | 2.20e-48 | 7.97e-01 | 0.1177 |
| 25972 | UNC50 | P4T-E | Human | Esophagus | ESCC | 4.27e-40 | 9.90e-01 | 0.1323 |
| 25972 | UNC50 | P5T-E | Human | Esophagus | ESCC | 2.28e-22 | 4.78e-01 | 0.1327 |
| 25972 | UNC50 | P8T-E | Human | Esophagus | ESCC | 6.84e-54 | 8.18e-01 | 0.0889 |
| 25972 | UNC50 | P9T-E | Human | Esophagus | ESCC | 1.46e-28 | 7.33e-01 | 0.1131 |
| 25972 | UNC50 | P10T-E | Human | Esophagus | ESCC | 1.79e-58 | 1.07e+00 | 0.116 |
| 25972 | UNC50 | P11T-E | Human | Esophagus | ESCC | 8.22e-23 | 8.90e-01 | 0.1426 |
| 25972 | UNC50 | P12T-E | Human | Esophagus | ESCC | 1.27e-52 | 8.65e-01 | 0.1122 |
| 25972 | UNC50 | P15T-E | Human | Esophagus | ESCC | 1.47e-30 | 7.68e-01 | 0.1149 |
| 25972 | UNC50 | P16T-E | Human | Esophagus | ESCC | 4.26e-39 | 7.22e-01 | 0.1153 |
| 25972 | UNC50 | P17T-E | Human | Esophagus | ESCC | 4.12e-02 | 2.86e-01 | 0.1278 |
| 25972 | UNC50 | P19T-E | Human | Esophagus | ESCC | 1.13e-16 | 8.99e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UNC50 | SNV | Missense_Mutation | novel | c.456N>A | p.Phe152Leu | p.F152L | protein_coding | tolerated(0.31) | benign(0.018) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UNC50 | SNV | Missense_Mutation | c.403N>T | p.Val135Leu | p.V135L | protein_coding | tolerated(0.12) | benign(0.175) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
| UNC50 | deletion | Frame_Shift_Del | rs752307344 | c.578delN | p.Phe195SerfsTer7 | p.F195Sfs*7 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| UNC50 | insertion | In_Frame_Ins | novel | c.318_319insGTCGGTAGCCAAATGTTTCTTCAGAATACGTGTAAA | p.Ser106_Ile107insValGlySerGlnMetPheLeuGlnAsnThrCysLys | p.S106_I107insVGSQMFLQNTCK | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |||
| UNC50 | SNV | Missense_Mutation | novel | c.25A>G | p.Arg9Gly | p.R9G | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UNC50 | SNV | Missense_Mutation | c.175N>T | p.Arg59Trp | p.R59W | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| UNC50 | SNV | Missense_Mutation | c.599N>G | p.Ile200Ser | p.I200S | protein_coding | deleterious(0) | benign(0.086) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| UNC50 | SNV | Missense_Mutation | novel | c.443N>A | p.Thr148Asn | p.T148N | protein_coding | deleterious(0.02) | probably_damaging(0.92) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UNC50 | SNV | Missense_Mutation | c.520N>G | p.Phe174Val | p.F174V | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| UNC50 | SNV | Missense_Mutation | novel | c.87N>T | p.Gln29His | p.Q29H | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |